The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wid...
Guardado en:
Autores principales: | José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/202fb31b049d40719834b2f73826e988 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010) -
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009) -
Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006) -
Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel AB, et al.
Publicado: (2018) -
Consideraciones sobre las complicaciones motoras y neurotoxicidad de la levodopa en la enfermedad de Parkinson
por: Venegas F.,Pablo
Publicado: (2005)